PPARγ-activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant KRAS mice

• Published in: Oncoimmunology 2018-05, Vol.7 (5), p.e1423168-e1423168
• Main Authors: Gutting, Tobias, Weber, Christian A., Weidner, Philip, Herweck, Frank, Henn, Sarah, Friedrich, Teresa, Yin, Shuiping, Kzhyshkowska, Julia, Gaiser, Timo, Janssen, Klaus-Peter, Reindl, Wolfgang, Ebert, Matthias P. A., Burgermeister, Elke
• Format: Article
• Language: English
• Subjects: colorectal cancer; macrophages; Original Research; PPAR; RAS
• ISSN: 2162-4011; 2162-402X; 2162-402X
• DOI: 10.1080/2162402X.2017.1423168

To identify novel hubs for cancer immunotherapy, we generated C57BL/6J mice with concomitant deletion of the drugable transcription factor PPARγ and transgenic overexpression of the mutant KRASG12V oncogene in enterocytes. Animals developed epithelial hyperplasia, transmural inflammation and serrated adenomas in the small intestine with infiltration of CD3+ FOXP3+ T-cells and macrophages into the lamina propria of the non-malignant mucosa. Within serrated polyps, CD3+ CD8+ T-cells and phosphorylated ERK1/2 were reduced and the senescence marker P21 and macrophage counts up-regulated, indicative of an immunosuppressive tissue microenvironment. Treatment of mutant KRASG12V mice with the PPARγ-agonist rosiglitazone augmented M1 macrophage numbers, reduced IL4 expression and diminished polyp load in mice. Rosiglitazone also promoted M1 polarisation of human THP1-derived macrophages and decreased Il4 mRNA in isolated murine lymphocytes. Thus, inhibition of the oncogenic driver mutant RAS by PPARγ in epithelial and immune cell compartments may be a future target for the prevention or treatment of human malignancies associated with intestinal inflammation.